Filing Flows › Health Care › Xilio Therapeutics (XLO)
Xilio Therapeutics (XLO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Xilio Therapeutics (XLO) Q2 2026 earnings results →
Q2 2026 Revenue up 131% year over year to $18.7M · 34¢ of every $1 of revenue lost · operating margin -18.7%
Xilio Therapeutics made $18.7M in Q2 2026 (+131% Y/Y). Operating margin -18.7%, net loss $6.4M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $18.7M in Q2 2026, up 131% year over year and up 48% from the previous quarter.
Operating costs exceeded revenue by $3.5M, an operating margin of -18.7%. Total costs fell 1% while revenue rose 131%. The quarter ended with a net loss of $6.4M, narrower than the previous quarter's $9.5M loss.
Operating cash flow was −$18.8M. Non-cash charges added back $331K of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items used $14.3M. Capital expenditures of $19K exceeded it, leaving free cash flow of −$18.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $18.7M | +131% | -18.7% | −$6.4M | −$18.8M |
| Q1 2026 | 10-Q | May 12, 2026 | $12.6M | +332% | -111.6% | −$9.5M | −$22.3M |
| Q4 2025 | 10-K | Mar 23, 2026 | $13.7M | +694% | -86.5% | $10.4M | −$2.0M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $19.1M | +742% | -10.1% | −$16.3M | −$17.5M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $8.1M | +243% | -177.7% | −$15.8M | −$14.5M |
| Q1 2025 | 10-Q | May 8, 2025 | $2.9M | — | -472.7% | −$13.3M | $29.0M |
| Q4 2024 | 10-K | Mar 11, 2025 | $1.7M | — | -790.5% | −$13.1M | −$14.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Xilio Therapeutics
We are a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. We are leveraging our proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including masked antibodies, bispecifics, cytokines and immune cell engagers. Current I-O therapies have curative potential for patients with cancer. However, their potential is significantly curtailed by systemic toxicity that results from activity of the therapeutic molecule outside the tumor microenvironment.
In its own words, from its 10-K, filed Mar 11, 2025.
Xilio Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +131% against the peers' median +10%. Operating margin: -18.7% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| XLO Xilio Therapeutics | Q2 2026 | $18.7M | +131% | -18.7% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Xilio Therapeutics 10-Q on SEC EDGAR · CIK 1840233 · Pharmaceutical Preparations
13F: who owns XLO and who is buying
More on XLO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results